These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12407956)

  • 1. Antipsychotics and QTc interval prolongation.
    White CM
    Conn Med; 2002 Aug; 66(8):461-3. PubMed ID: 12407956
    [No Abstract]   [Full Text] [Related]  

  • 2. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].
    Finzel M; Fric M; Laux G
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S178-80. PubMed ID: 15570546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine.
    Vieweg WV; Schneider RK; Wood MA
    Acta Psychiatr Scand; 2005 Oct; 112(4):318-22; author reply 322. PubMed ID: 16156840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulpiride induced torsade de pointes.
    Huang BH; Hsia CP; Chen CY
    Int J Cardiol; 2007 Jun; 118(3):e100-2. PubMed ID: 17408770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antipsychotic pharmacotherapy for delirious syndromes - only temporary, symptom-oriented and considering QTc time].
    Schwerthöffer D; Förstl H; Fatke B
    MMW Fortschr Med; 2019 Jul; 161(Suppl 5):1-6. PubMed ID: 31313266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probable Acquired QTc Prolongation and Subsequent Torsades de Pointes Attributable to Quetiapine.
    Giancaterino S; Solimine S
    Prim Care Companion CNS Disord; 2017 Nov; 19(6):. PubMed ID: 29190419
    [No Abstract]   [Full Text] [Related]  

  • 9. [Reduction of prolonged QTc-interval related risks in treatment with neuropharmacological drugs. Recommendations for clinical practice].
    van de Kraats GB; Slob J; Tenback DE
    Tijdschr Psychiatr; 2007; 49(1):43-7. PubMed ID: 17225205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block.
    Ginwalla M; Biblo LA; Paydak H
    WMJ; 2009 Feb; 108(1):48-50. PubMed ID: 19326637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced block of cardiac HERG potassium channels and development of torsade de pointes arrhythmias: the case of antipsychotics.
    Calderone V; Testai L; Martinotti E; Del Tacca M; Breschi MC
    J Pharm Pharmacol; 2005 Feb; 57(2):151-61. PubMed ID: 15720777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. QTc prolongation and torsades de pointes associated with methadone therapy.
    Routhier DD; Katz KD; Brooks DE
    J Emerg Med; 2007 Apr; 32(3):275-8. PubMed ID: 17394991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of QTc in patients receiving chronic methadone therapy.
    Cruciani RA; Sekine R; Homel P; Lussier D; Yap Y; Suzuki Y; Schweitzer P; Yancovitz SR; Lapin JA; Shaiova L; Sheu RG; Portenoy RK
    J Pain Symptom Manage; 2005 Apr; 29(4):385-91. PubMed ID: 15857742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin and torsade de pointes.
    Dale KM; Lertsburapa K; Kluger J; White CM
    Ann Pharmacother; 2007 Feb; 41(2):336-40. PubMed ID: 17284508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
    Amankwa K; Krishnan SC; Tisdale JE
    Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azithromycin-induced torsade de pointes.
    Huang BH; Wu CH; Hsia CP; Yin Chen C
    Pacing Clin Electrophysiol; 2007 Dec; 30(12):1579-82. PubMed ID: 18070319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsade de pointes associated with low-dose amisulpride: a case report.
    Chung AK; Chua SE
    J Psychopharmacol; 2010 Mar; 24(3):433-5. PubMed ID: 18957479
    [No Abstract]   [Full Text] [Related]  

  • 19. Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol.
    Tisdale JE; Kovacs R; Mi D; McCabe GP; Cariera BL; Sharma N; Rosman H
    Pharmacotherapy; 2007 Feb; 27(2):175-82. PubMed ID: 17253907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic agents associated with QT interval prolongation.
    Olsen KM
    J Fam Pract; 2005 Jun; Suppl():S8-S14. PubMed ID: 15938993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.